Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
National Wilms Tumor Study-5
NCT00002611Phase 3Completed
- Sponsor
- Children's Oncology Group
- Start
- Jul 1995
- Primary completion
- Jun 2002
- Modality
- DNA Intercalators/Alkylators, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 7
01
Overview
Phase 3, open-label trial of actinomycin D, vincristine, doxorubicin, cyclophosphamide, etoposide and 1 more in Wilms' tumor, clear cell sarcoma of the kidney (CCSK) and Rhabdoid Tumor of the Kidney (RTK) (9 arms), sponsored by Children's Oncology Group. Primary endpoint: Progression-Free Survival. Started Jul 1995; status: completed.
02
Drugs
actinomycin Dvincristinedoxorubicincyclophosphamideetoposide
03
Conditions
Wilms' tumorclear cell sarcoma of the kidney (CCSK)Rhabdoid Tumor of the Kidney (RTK)
Beyond the preview
Go deeper on NCT00002611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002611.